GYRE

Conviction 38HealthcareScan · Mon, Aug 10, 2026

GYRE$6.71+0.60%

ResistanceSupportVol 14Insider sell

Vol MA14 65.98K

May 11May 28Jun 16Jul 6Jul 23Aug 10

GYRE THERAPEUTICS, INC.PHARMACEUTICAL PREPARATIONSwww.gyretx.com ↗

Price6.71

Change+0.60%

Gap+0.67%

Rel volume4.99×

Avg volume62.04K

Avg $ vol386.84K

SMA 206.14

SMA 506.23

SMA 2007.25

Price vs 50+7.75%

Price vs 200-7.39%

MA stackmixed

50/200 cross—

Supertrendup · 5.68

RSI (14)60

MACD hist0.09

MACD crossbull · 3d

Stoch %K / %D96 / 94

ADX (14)18

+DI / −DI29 / 16

RSI divergence—

MACD divergenceBullish

ATR %+4.64%

ADR %4.66%

52w high8.87

52w low5.56

From 52w high-24.35%

Above 52w low+20.68%

New 52w highNo

SqueezeOff

Bollinger width18.94%

%B0.99

Donchian pos95.61%

Donchian high6.76

Donchian low5.62

AVWAP (52w high)7.25

vs AVWAP high-7.48%

AVWAP (52w low)6.32

vs AVWAP low+6.24%

OBV trendUp

Chaikin MF (20)0.07

Today vs 20d4.99×

Avg vol (14d)65.98K

Avg vol (20d)62.04K

Avg $ vol (20d)386.84K

Market cap—

RS 3m (vs SPY)-11.35%

RS 6m (vs SPY)-25.30%

RS line new highNo

Trend template2/8

Technical rank44.4

1 week+9.82%

1 month+2.91%

3 months-10.17%

6 months-14.85%

1 year-6.81%

YTD-1.47%

P/E75.05

P/B6.87

P/S6.36

P/FCF-4119.67

EPS0.0200

Div yield—

ROE9.15%

ROA4.96%

Debt/Eq0.01

Current4.26

EV/EBITDA50.03

Gross margin87.38%

Net margin8.47%

Rev growth10.24%

EPS growth-44.80%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value698.87M

Revenue29.11M

Net income-14.27M

Gross profit28.94M

Free cash flow-180K

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out97.03M

Employees618

ListedTue, Oct 31, 2023

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction38 / 100

Pattern quality—

Tech rank44.4 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance7.08

Support5.62

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GYRE

All disclosures →

No recent disclosed trades by Congress in GYRE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GYRE · 7 buys · 3 sells

Insider	Side	Shares	Value	Traded	Filed
Carmichael Gordon Director · Stock Option (Right to Buy) · 2026-06-10	Grant	40K	—	2026-06-10	2026-06-30
Epstein David M. Director · Stock Option (Right to Buy) · 2026-06-10	Grant	40K	—	2026-06-10	2026-06-30
Nussbaum Rodney L Director · Stock Option (Right to Buy) · 2026-06-10	Grant	40K	—	2026-06-10	2026-06-30
Zhang Ping Director · Stock Option (Right to Buy) · 2026-06-10	Grant	40K	—	2026-06-10	2026-06-30
Parry Renate Director · Stock Option (Right to Buy) · 2026-06-10	Grant	40K	—	2026-06-10	2026-06-30
Weng Dan Director · Stock Option (Right to Buy) · 2026-06-10	Grant	40K	—	2026-06-10	2026-06-30
Ye Weiguo Chief Operating Officer · Stock Option (Right to Buy) · 2026-06-18	Exercise	3K	—	2026-06-18	2026-06-22
Ye Weiguo Chief Operating Officer · Common Stock · 2026-06-18	Exercise	3K	$2K	2026-06-18	2026-06-22
Ye Weiguo Chief Operating Officer · Common Stock · 2026-06-18	Sell	3K	$19K	2026-06-18	2026-06-22
Ye Weiguo Chief Operating Officer · Stock Option (Right to Buy) · 2026-06-10	Exercise	5K	—	2026-06-10	2026-06-22

SEC filings

EDGAR filings in GYRE · 8 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.